Evidence map›Paper›PMID 35273497›Full record

ArticleFrontiers in pharmacology2022

A Physiologically Based Pharmacokinetic Model for Studying the Biowaiver Risk of Biopharmaceutics Classification System Class I Drugs With Rapid Elimination: Dexketoprofen Trometamol Case Study.

Xian Zhang, Xuxiao Ye, Kuan Hu, Wenping Li, Wenqian Li, Qingqing Xiao, Lin Chen, Jin Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xian ZhangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Xuxiao YeCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Kuan HuCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Wenping LiCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Wenqian LiCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Qingqing XiaoMosim Pharmaceutical Technology Co., Ltd., Shanghai, China.
Lin ChenCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
Jin YangCenter of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, China.
China Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biowaiver based on the biopharmaceutics classification system (BCS) has been widely used in the global market for the approval of new generic drug products to avoid unnecessary

Indexed as

bioequivalencebiowaiverdexketoprofen trometamolgastric emptyingphysiologically based pharmacokinetic model

Identifiers

PMID35273497
PMCPMC8904038
OpenAlexW4210966512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.